Peramivir

Kathryn Dzintars, Pharm.D., BCPS, Paul A. Pham, Pharm.D. BCPS
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID
Peramivir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

NON-FDA APPROVED USES

  • Treatment of influenza for hospitalized adult and pediatric patients for whom therapy with an IV anti-influenza drug is needed.
    • Limited data available to support efficacy in complicated influenza, or influenza requiring hospitalization or influenza > 48h duration[7].
    • Peramivir can be considered for treatment failure occurring with use of currently approved anti-influenza drugs (e.g., oseltamivir and zanamivir) and in patients who are unable to take oral or inhaled anti-viral therapy.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

NON-FDA APPROVED USES

  • Treatment of influenza for hospitalized adult and pediatric patients for whom therapy with an IV anti-influenza drug is needed.
    • Limited data available to support efficacy in complicated influenza, or influenza requiring hospitalization or influenza > 48h duration[7].
    • Peramivir can be considered for treatment failure occurring with use of currently approved anti-influenza drugs (e.g., oseltamivir and zanamivir) and in patients who are unable to take oral or inhaled anti-viral therapy.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: December 6, 2017